Alphabet Selloff Puts AI Spending in Focus
Yahoo Finance ·
Alphabet Selloff Puts AI Spending in Focus Moz Farooque ACCA Fri, July 24, 2026 at 8:38 AM EDT 1 min read GOOG This article first appeared on GuruFocus . Alphabet ( NASDAQ:GOOGL ) slipped below its 200-day moving average for the first time in more than a year after an earnings-driven selloff knocked nearly 7% off the stock. Shares closed Thursday at $318.34, down 6.9%, as investors looked past solid quarterly results and focused instead on the rising cost of Alphabet's artificial intelligence buildout. Warning! GuruFocus has detected 6 Warning Sign with LLY. Is GOOGL fairly valued? Test your thesis with our free DCF calculator. The 200-day moving average is widely watched as a gauge of long-term momentum. A single close below it does not confirm a breakdown, but staying under the level for several sessions could make traders more cautious.
AI 시장 분석
Alphabet's (GOOGL) stock plummeted 6.9% following its earnings release, falling below its 200-day moving average for the first time in about a year. The market focused on concerns over rising costs from building AI infrastructure rather than the solid quarterly earnings, triggering a sell-off. The deviation from the 200-day line can be interpreted as a sign of weakening long-term momentum, requiring a cautious approach from investors.
하락 영향
- AI — As Alphabet's surge in AI infrastructure investment costs is confirmed, concerns over short-term profitability deterioration for big tech companies are growing, negatively impacting investor sentiment.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 53% · Bearish (Short) 47%
512 participants
Related News
- Newmont posts Q2 earnings topper despite lower gold prices
- SK hynix, Samsung set to sign sizable supply deals with US companies: report
- Surgery Partners announces $1.15B deal to sell stakes in Idaho Falls Facilities
- S&P 500 forward P/E falls below 20x as valuation multiple eases
- Texas A&M Engineering Experiment Station picks Dell to build AI platform for national research
- Roche launches FDA-cleared PCR test; expands women's health portfolio
